JP5735417B2 - 減数分裂期キネシンに関連する疾患を治療する方法 - Google Patents

減数分裂期キネシンに関連する疾患を治療する方法 Download PDF

Info

Publication number
JP5735417B2
JP5735417B2 JP2011511802A JP2011511802A JP5735417B2 JP 5735417 B2 JP5735417 B2 JP 5735417B2 JP 2011511802 A JP2011511802 A JP 2011511802A JP 2011511802 A JP2011511802 A JP 2011511802A JP 5735417 B2 JP5735417 B2 JP 5735417B2
Authority
JP
Japan
Prior art keywords
hset
cells
cell
kinesin
centrosomes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011511802A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011525174A (ja
JP2011525174A5 (https=
Inventor
デイビッド ペルマン
デイビッド ペルマン
Original Assignee
デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド
デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド, デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド filed Critical デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド
Publication of JP2011525174A publication Critical patent/JP2011525174A/ja
Publication of JP2011525174A5 publication Critical patent/JP2011525174A5/ja
Application granted granted Critical
Publication of JP5735417B2 publication Critical patent/JP5735417B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5026—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell morphology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2011511802A 2008-05-30 2009-05-28 減数分裂期キネシンに関連する疾患を治療する方法 Expired - Fee Related JP5735417B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5759008P 2008-05-30 2008-05-30
US61/057,590 2008-05-30
PCT/US2009/045406 WO2009155025A1 (en) 2008-05-30 2009-05-28 Methods of treating a meiotic kinesin-associated disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015020184A Division JP6132409B2 (ja) 2008-05-30 2015-02-04 減数分裂期キネシンに関連する疾患を治療する方法

Publications (3)

Publication Number Publication Date
JP2011525174A JP2011525174A (ja) 2011-09-15
JP2011525174A5 JP2011525174A5 (https=) 2012-07-12
JP5735417B2 true JP5735417B2 (ja) 2015-06-17

Family

ID=41110533

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2011511802A Expired - Fee Related JP5735417B2 (ja) 2008-05-30 2009-05-28 減数分裂期キネシンに関連する疾患を治療する方法
JP2015020184A Expired - Fee Related JP6132409B2 (ja) 2008-05-30 2015-02-04 減数分裂期キネシンに関連する疾患を治療する方法
JP2016108400A Expired - Fee Related JP6184556B2 (ja) 2008-05-30 2016-05-31 減数分裂期キネシンに関連する疾患を治療する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2015020184A Expired - Fee Related JP6132409B2 (ja) 2008-05-30 2015-02-04 減数分裂期キネシンに関連する疾患を治療する方法
JP2016108400A Expired - Fee Related JP6184556B2 (ja) 2008-05-30 2016-05-31 減数分裂期キネシンに関連する疾患を治療する方法

Country Status (12)

Country Link
US (3) US8629118B2 (https=)
EP (1) EP2315594B1 (https=)
JP (3) JP5735417B2 (https=)
KR (1) KR20110022000A (https=)
CN (1) CN102316877A (https=)
AU (1) AU2009260527A1 (https=)
BR (1) BRPI0912043A2 (https=)
CA (1) CA2725911A1 (https=)
EA (1) EA201071422A1 (https=)
ES (1) ES2633930T3 (https=)
MX (1) MX2010012931A (https=)
WO (1) WO2009155025A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9486449B2 (en) 2007-10-09 2016-11-08 Malka COHEN-ARMON Cancer therapy
CA2725911A1 (en) * 2008-05-30 2009-12-23 Dana-Farber Cancer Institute, Inc. Methods of treating a meiotic kinesin-associated disease
CA2868302A1 (en) 2012-03-23 2013-09-26 Dennis M. Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
US20150309031A2 (en) * 2013-12-05 2015-10-29 Novazoi Theranostics Compositions and methods for prognosis and treatment of cancer
WO2015130953A1 (en) * 2014-02-28 2015-09-03 Novazoi Theranostics, Inc. Method for determining the risk profile of neoplastic tissue
CN113456633A (zh) * 2021-06-11 2021-10-01 广西医科大学 红海海绵素a在制备抗肺癌侵袭转移药物中的应用
AU2023205435A1 (en) 2022-01-10 2024-08-22 Cancer Research Horizons Substituted heterocycles as hset inhibitors
CN115327125A (zh) * 2022-07-14 2022-11-11 宁波大学 一种蛋白质inf2在制备肝癌诊断标志物中的应用
CN120265629A (zh) 2022-11-07 2025-07-04 默克专利股份公司 被取代的双环和三环hset抑制剂

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
AU4367700A (en) * 1999-04-20 2000-11-02 Cytokinetics, Inc. Human kinesins and methods of producing and purifying human kinesins
US6410254B1 (en) * 1999-05-18 2002-06-25 Cytokinetics Compositions and assays utilizing ADP or phosphate for detecting protein modulators
US7202051B1 (en) * 1999-05-18 2007-04-10 Cytokinetics, Inc. Compositions and assays utilizing ADP or phosphate for detecting protein modulators
US7416856B2 (en) * 1999-05-18 2008-08-26 Cytokinetics, Inc. High sensitivity assay for detection of nucleoside diphosphate production
US6743599B1 (en) * 1999-05-18 2004-06-01 Cytokinetics, Inc. Compositions and assays utilizing ADP or phosphate for detecting protein modulators
MXPA03008691A (es) 2001-03-29 2003-12-12 Bristol Myers Squibb Co Metodo para tratamiento de enfermedades proliperativas usando inhibidores eg5.
US20040009156A1 (en) * 2001-10-12 2004-01-15 Christoph Reinhard Antisense therapy using oligonucleotides that target human kinesin genes for treatment of cancer
US7163927B2 (en) * 2002-05-23 2007-01-16 Isis Pharmaceuticals, Inc. Antisense modulation of kinesin-like 1 expression
US20050100508A1 (en) * 2003-11-12 2005-05-12 Nichols M. J. Methods for identifying drug combinations for the treatment of proliferative diseases
US20070026424A1 (en) * 2005-04-15 2007-02-01 Powell Charles A Gene profiles correlating with histology and prognosis
US20080051463A1 (en) * 2006-08-04 2008-02-28 Aeterna Zentaris Gmbh Anthracene compounds and their use for treating benign and malignant tumor disorders
WO2008015265A1 (de) 2006-08-04 2008-02-07 Æterna Zentaris Gmbh Anthracen-derivate und deren verwendung zur behandlung gutartiger und bösartiger tumorerkrankungen
US20100145131A1 (en) 2007-05-01 2010-06-10 Helena Grinberg-Rashi Methods and kits for predicting cancer metastasis
CA2725911A1 (en) 2008-05-30 2009-12-23 Dana-Farber Cancer Institute, Inc. Methods of treating a meiotic kinesin-associated disease

Also Published As

Publication number Publication date
US9645136B2 (en) 2017-05-09
JP6132409B2 (ja) 2017-05-24
CN102316877A (zh) 2012-01-11
WO2009155025A1 (en) 2009-12-23
US20150111786A1 (en) 2015-04-23
KR20110022000A (ko) 2011-03-04
US20140106344A1 (en) 2014-04-17
US20110190374A1 (en) 2011-08-04
JP2015131813A (ja) 2015-07-23
US8629118B2 (en) 2014-01-14
EP2315594B1 (en) 2017-05-17
AU2009260527A1 (en) 2009-12-23
CA2725911A1 (en) 2009-12-23
US8962592B2 (en) 2015-02-24
EA201071422A1 (ru) 2011-08-30
JP2011525174A (ja) 2011-09-15
JP6184556B2 (ja) 2017-08-23
EP2315594A1 (en) 2011-05-04
MX2010012931A (es) 2011-02-24
JP2016169224A (ja) 2016-09-23
BRPI0912043A2 (pt) 2019-09-24
ES2633930T3 (es) 2017-09-26

Similar Documents

Publication Publication Date Title
JP6184556B2 (ja) 減数分裂期キネシンに関連する疾患を治療する方法
García-Huerta et al. Insulin-like growth factor 2 (IGF2) protects against Huntington’s disease through the extracellular disposal of protein aggregates
Yoshida et al. CDC6 interaction with ATR regulates activation of a replication checkpoint in higher eukaryotic cells
Gozdz et al. GSK3α and GSK3β phosphorylate Arc and regulate its degradation
Crasto et al. Luteolin inhibition of V‐ATPase a3–d2 interaction decreases osteoclast resorptive activity
Zhu et al. CIB2 negatively regulates oncogenic signaling in ovarian cancer via sphingosine kinase 1
Chen et al. CircFam190a: a critical positive regulator of osteoclast differentiation via enhancement of the AKT1/HSP90β complex
CN105358173A (zh) 靶向癌症治疗的egfr-sglt1相互作用
US20130344083A1 (en) Modulation of histone h2b monoubiquitination and treatment of cancer
Chudakova et al. Integrin-associated Lyn Kinase Promotes Cell Survival by Suppressing Acid Sphingomyelinase Activity∗
Gardner et al. Geminin overexpression prevents the completion of topoisomerase IIα chromosome decatenation, leading to aneuploidy in human mammary epithelial cells
US10626397B2 (en) Therapeutic compositions for breast cancer containing protein kinase D1 inhibitor
Guerra et al. Essential role of CK2α for the interaction and stability of replication fork factors during DNA synthesis and activation of the S-phase checkpoint
JP2018520164A (ja) プロテアソームインヒビターと組み合わせてｍｅｋインヒビターを投与することによりがんを処置する方法
Yund et al. Hic-5 is required for fetal gene expression and cytoskeletal organization of neonatal cardiac myocytes
CN114617878A (zh) Ck2抑制剂在制备抗衰药物中的应用
US12209111B2 (en) Targeting P18 for mTOR-related disorders
Odii Roles of Transglutaminase 2 in development of drug resistance and metastasis by cancer cells
Salmonowicz Mitochondrial dysfunction as a driver of cellular senescence
De Benedetti et al. Targeting the TLK1/NEK1 Axis in PCa
de Ribeiro Pinho Nucleolar stress as an aging hallmark: the role of NOL12 and FoxM1
Memarzadeh Endosomal Trafficking and Exosomal Secretion of Egfrviii
Schmidt Understanding and modulating synaptic dysfunction in Huntington disease
Sharpe The discovery of a novel, Ras-mediated NORE1A/PMLIV tumor suppressor complex.
Chen The role of cad, flash and fam129b in cancer cell survial and apoptosis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120525

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120525

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140404

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150204

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150408

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150416

R150 Certificate of patent or registration of utility model

Ref document number: 5735417

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees